Osteopore Management

Management criteria checks 1/4

Osteopore's CEO is Yujing Lim, appointed in Sep 2019, has a tenure of 4.67 years. total yearly compensation is A$202.25K, comprised of 91.8% salary and 8.2% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth A$12.11K. The average tenure of the management team and the board of directors is 1.3 years and 1.3 years respectively.

Key information

Yujing Lim

Chief executive officer

AU$202.2k

Total compensation

CEO salary percentage	91.8%
CEO tenure	4.7yrs
CEO ownership	0.1%
Management average tenure	1.3yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yujing Lim's remuneration changed compared to Osteopore's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	AU$202k	AU$186k	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	n/a	n/a	-AU$5m
Mar 31 2023	n/a	n/a	-AU$5m
Dec 31 2022	AU$164k	AU$149k	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	n/a	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	AU$132k	AU$118k	-AU$4m
Sep 30 2021	n/a	n/a	-AU$3m
Jun 30 2021	n/a	n/a	-AU$3m
Mar 31 2021	n/a	n/a	-AU$2m
Dec 31 2020	AU$124k	AU$109k	-AU$2m
Sep 30 2020	n/a	n/a	-AU$2m
Jun 30 2020	n/a	n/a	-AU$2m
Mar 31 2020	n/a	n/a	-AU$2m
Dec 31 2019	AU$39k	AU$34k	-AU$2m

Compensation vs Market: Yujing's total compensation ($USD134.86K) is below average for companies of similar size in the Australian market ($USD298.11K).

Compensation vs Earnings: Yujing's compensation has increased whilst the company is unprofitable.

CEO

Yujing Lim

4.7yrs

Tenure

AU$202,246

Compensation

Dr. Yujing Lim, Ph. D. (Singapore), is Chief Executive Officer of Osteopore Limited from July 18, 2023 and serves as Chief Technology Officer May 01, 2022. Dr. Lim joined the Osteopore Limited on November...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kei Wei Leong	Executive Chairman	2.8yrs	AU$214.90k	0.011% A$ 962.3
Yujing Lim	CEO & CTO	4.7yrs	AU$202.25k	0.14% A$ 12.1k
Shu Voon	Financial Controller	1.3yrs	no data	no data
Khoon Seng Goh	Global Marketing Director	less than a year	AU$212.90k	0% A$ 0
Kellie Davis	Company Secretary	1.3yrs	no data	no data

1.3yrs

Average Tenure

Experienced Management: OSX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kei Wei Leong	Executive Chairman	2.8yrs	AU$214.90k	0.011% A$ 962.3
David Yeow	Member of Advisory Board	1.3yrs	no data	no data
Swee Hin Teoh	Non Executive Director	4.9yrs	AU$46.36k	0.55% A$ 45.8k
Daniel Ow	Independent Non-Executive Director	2.6yrs	AU$46.36k	no data
Greg Rudd	Member of Advisory Board	1.3yrs	no data	no data
Michael Wagels	Member of Advisory Board	1.3yrs	no data	no data
Joy Song	Member of Advisory Board	1.3yrs	no data	no data
Samintharaj Kumar	Member of Advisory Board	1.3yrs	no data	no data
James Tan	Member of Advisory Board	1.3yrs	no data	no data
GK Ananda	Member of Advisory Board	1.3yrs	no data	no data
Michael Keenan	Director	less than a year	AU$18.24k	no data

1.3yrs

Average Tenure

Experienced Board: OSX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Osteopore Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

Recent updates

New major risk - Shareholder dilution

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Osteopore Limited has filed a Follow-on Equity Offering in the amount of AUD 2.99532 million.

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

Osteopore Limited Enters Orthopaedic Market in Great Britain

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Less than half of directors are independent

Osteopore Limited (ASX:OSX) agreed to acquire Businesses Of Lomic Korea, 3D Aesthetic Solutions, 3D Healthcare Solutions And 3D Aesthetic Medical Lim Jae Hoon from Lim Jae Hoon for AUD2.05 million.

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Insider recently bought AU$1.9m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Appointment of Dr. Lim Jing as Chief Operating Officer

Osteopore Limited, Annual General Meeting, May 31, 2022

Less than half of directors are independent

Osteopore Limited Announces Resignation of Vlado Bosanac as Non-Executive Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Non Executive Chairman Brett Sandercock has left the company

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Osteopore Limited Announces A Cooperation Agreement with Terumo Blood and Cell Technologies

Osteopore International Collaborates with Maastricht University Medical Centre to Develop Implant Solution That Prevents Leg Amputations

Osteopore Limited Signs Distribution Agreement with MTG Medizintechnik Göhl

Osteopore Limited Announce the Appointment of Carl Runde as Chief Financial Officer

First half earnings released

Osteopore Limited has completed a Follow-on Equity Offering in the amount of AUD 8.5 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure